Characteristics and Treatment Outcomes of Pediatric Langerhans Cell Histiocytosis with Thymic Involvement
- 19 January 2022
- journal article
- research article
- Published by Elsevier BV in The Journal of Pediatrics
- Vol. 244, 194-202.e5
- https://doi.org/10.1016/j.jpeds.2022.01.007
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Positive and negative selection of the T cell repertoire: what thymocytes see (and don't see)Nature Reviews Immunology, 2014
- Thymus and mediastinal node involvement in childhood langerhans cell histiocytosis: Long‐term follow‐up from the French national cohortPediatric Blood & Cancer, 2013
- Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosisBlood, 2013
- Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work‐up, and treatment for patients till the age of 18 yearsPediatric Blood & Cancer, 2012
- Recurrent BRAF mutations in Langerhans cell histiocytosisBlood, 2010
- Reactivations in Multisystem Langerhans Cell Histiocytosis: Data of the International LCH RegistryThe Journal of Pediatrics, 2008
- CD8+ T cell efficacy in vaccination and diseaseNature Medicine, 2008
- Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000–2004Pediatric Blood & Cancer, 2008
- CD8 T Cell Responses to Infectious PathogensAnnual Review of Immunology, 2003
- The thymus in Langerhans' cell histiocytosisPediatric Radiology, 1999